DUBLIN--(BUSINESS WIRE)--The "Liquid Biopsy Market - Global Drivers, Restraints, Opportunities, Trends, and Forecasts: 2017-2023" report has been added to ResearchAndMarkets.com's offering.
The Global Liquid Biopsy Market is estimated to witness a CAGR of 24.1% during the forecast period 2017-2023
The global liquid biopsy market by biomarker type is segmented into circulating tumor cell (CTC), cell-free DNA (cfDNA), extracellular vesicles, and others. Cell-free DNA (cfDNA) segment was the largest segment in 2016 due to its wide range of application in prenatal testing, transplantation diagnostics, and oncology.
The global liquid biopsy market by sample type is segmented into blood and others. Blood sample occupied the major market share in 2016, as most of the tests currently available in the market are blood-based tests.
The global liquid biopsy market by application is segmented into cancer and non-cancer applications. The cancer segment occupies the largest market share and is expected to be the fastest growing segment during the forecast period. Cancer application is further segmented by cancer indication and clinical application.
The global liquid biopsy market by end-users is segmented into hospital and reference laboratories, academic and research institutes, and others. Hospital and reference laboratories occupied a major share of the liquid biopsy market in 2016 due to the increasing volume of test samples outsourced to this segment.
Biocept, Inc, F- Hoffmann-la Roche, Illumina, Inc, Natera Inc, Trovagene Inc., Qiagen N.V., Laboratory Corporation of America Holdings, Beijing Genomics Institute, Guardant Health, Inc., Genomic Health, MDx Health SA, Guardant Health, Inc., Myriad Genetics, Inc., and other predominate & niche players.
Key Topics Covered:
1 Industry Outlook
2 Report Outline
3 Market Snapshot
4 Market Outlook
5 Market Characteristics
6 Test Types: Market Size and Analysis
7 Application: Market Size and Analysis
8 Regions: Market Size and Analysis
9 Competitive Landscape
10 Vendor Profiles
- Beijing Genomics Institute
- Biocept, Inc.
- CareDx, Inc
- F.Hoffmann-La Roche Ltd
- Guardant Health
- Illumina, Inc.,
- Inivata Limited
- Laboratory Corporation of America Holdings (LABCORP)
- LifeCodexx AG
- Natera, Inc.
- Personal Genome Diagnostics
- Quest Diagnostics
For more information about this report visit https://www.researchandmarkets.com/research/dqc3mp/liquid_biopsy?w=4